Fifth Third Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Fifth Third Wealth Advisors's NBIX Position: Q3 2026 in Review
Fifth Third Wealth Advisors increased its Neurocrine Biosciences (NBIX) stake by 15% in Q3 2026, buying an estimated $81.3K and bringing the position to 3,920 shares worth $556K. The position accounts for 0.01% of the portfolio, ranked #483.
Fifth Third Wealth Advisors first reported a position in NBIX in Q2 2024 and has held it in 10 quarters since. The position peaked at $575K in Q2 2026. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Fifth Third Wealth Advisors held 3,920 shares of Neurocrine Biosciences worth $556K as of Q3 2026.
- Fifth Third Wealth Advisors bought 506 Neurocrine Biosciences shares in Q3 2026, an estimated $81.3K.
- Neurocrine Biosciences made up 0.01% of Fifth Third Wealth Advisors's portfolio in Q3 2026, its #483 holding.
- Fifth Third Wealth Advisors first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 10 quarters since.
- Fifth Third Wealth Advisors's Neurocrine Biosciences position peaked at $575K in Q2 2026.
- 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Fifth Third Wealth Advisors's 13F filing for Q3 2026, filed 22 Oct 2026.